790 reports of this reaction
1.2% of all PHENYLEPHRINE HYDROCHLORIDE reports
#18 most reported adverse reaction
MOBILITY DECREASED is the #18 most commonly reported adverse reaction for PHENYLEPHRINE HYDROCHLORIDE, manufactured by Belmora LLC. There are 790 FDA adverse event reports linking PHENYLEPHRINE HYDROCHLORIDE to MOBILITY DECREASED. This represents approximately 1.2% of all 65,609 adverse event reports for this drug.
Patients taking PHENYLEPHRINE HYDROCHLORIDE who experience mobility decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOBILITY DECREASED is a less commonly reported adverse event for PHENYLEPHRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to mobility decreased, the following adverse reactions have been reported for PHENYLEPHRINE HYDROCHLORIDE:
The following drugs have also been linked to mobility decreased in FDA adverse event reports:
MOBILITY DECREASED has been reported as an adverse event in 790 FDA reports for PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOBILITY DECREASED accounts for approximately 1.2% of all adverse event reports for PHENYLEPHRINE HYDROCHLORIDE, making it a notable side effect.
If you experience mobility decreased while taking PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.